Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (842)	1/13/1999 2:21:00 AM
From: Vector1	Read Replies (5) \| Respond to of 1686

HQ BGEN Report 2 Vincent next moved to the pipeline. Their stated goal is to have two or more drugs approved by 2001. The lead candidates are: Antova- (anti CD40 ligand) this is clearly the one they are most excited about. It has been through two phase IIs in ITP and Lupus and has been well tollerated. They are going to run as many as 6 different phase IIs for this compound in 99. HUGE POTENTIAL. AMEVIVE--fusion protien for moderate to severe psoriasis.Phase II date reported Q2 with Phase II commenced in 99. CVT 124--congestive heart failure. Phase II Q299 Pipeline is maturing nicely and they have a grade a ballance sheet to expand through acquisition and in licencing. Thoughts on Vincent. I think he is a very impressive guy who has been a winner everywhere he has gone. He brought a group of the key managers to the breakout and they give off the impression of being highly competent and focused managers. With this presentation and the Avonex momentum the street has already forgotten Tobin. What a mistake to leave. He should have held his ego in check and rode the wave for a few more years. I do give him credit. Biogen's rollout of Avonex was as well executed as any big pharma rollout. Biogen is a credit to the industry and is headed to another glorious year. If the Anti-CD40 MAB is successful in trials then in 5 years Biogen will have a bigger market cap than AMGEN and will be well on its way to becomming a pharma in its own right. V1